Patient-Reported Outcomes (PROs) from the Phase 2 TRANSCEND FL Study of Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory Follicular Lymphoma (FL)

被引：0

作者：

Cartron, Gillaume ^{[1
]}

Garcia-Sancho, Alejandro Martin ^{[2
]}

Reguera, Juan Luis ^{[3
]}

Dahiya, Saurabh ^{[4
]}

Guo, Shien ^{[5
]}

Shi, Ling ^{[5
]}

Eliason, Laurie ^{[6
]}

Kumar, Jinender ^{[6
]}

Farazi, Thalia ^{[7
]}

Fasan, Omotayo ^{[6
]}

Izutsu, Koji ^{[8
]}

机构：

[1] Montpellier Univ Hosp Ctr, Clin Hematol Dept, Montpellier, France

[2] Univ Salamanca, Hosp Univ Salamanca, IBSAL, CIBERONC, Salamanca, Spain

[3] Univ Seville, Dept Hematol, Univ Hosp Virgen Rocio IBIS, Seville, Spain

[4] Stanford Univ, Div Blood & Marrow Transplantat & Cellular Therap, Palo Alto, CA USA

[5] Evidera, Bethesda, MD USA

[6] Bristol Myers Squibb, Princeton, NJ USA

[7] Bristol Myers Squibb, San Francisco, CA USA

[8] Natl Canc Ctr, Tokyo, Japan

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-180175

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：4

共 50 条

[41] Outreach: Results from a Phase 2 Study of Lisocabtagene Maraleucel (liso-cel) Administered As Inpatient (Inpt) or Outpatient (Outpt) Treatment in the Nonuniversity Setting in Patients (Pts) with R/R Large B-Cell Lymphoma (LBCL)
Godwin, John E.
Mattar, Bassam
Maris, Michael
Bachier, Carlos
Stevens, Don
Hoda, Daanish
Varela, Juan C.
Cherry, Mohamad
Fanning, Suzanne
Essell, James
Yimer, Habte
Courtright, Jay
Sharman, Jeff P.
Espinola, Ricardo
Mailley, Connor
Avilion, Ariel
Ogasawara, Ken
Ou, San-San
Shaughnessy, Paul
BLOOD, 2021, 138
[42] Efficacy and safety of Tisagenlecleucel (Tisa-cel) in adult patients (Pts) with relapsed/refractory follicular lymphoma (r/r FL): Primary analysis of the phase 2 ELARA trial
Schuster, S.
Dickinson, M.
Dreyling, M.
Martinez-Lopez, J.
Kolstad, A.
Butler, J.
Ghosh, M.
Popplewell, L.
Chavez, J.
Bachy, E.
Kato, K.
Harigae, H.
Kersten, M. J.
Andreadis, C.
Riedell, P.
Zia, A.
Morisse, M. C.
Fowler, N. H.
Thieblemont, C.
ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 104 - 105
[43] Lisocabtagene Maraleucel (liso-cel) for Treatment of Second-Line Transplant Noneligible (TNE) Relapsed/Refractory (R/R) Aggressive Non-Hodgkin Lymphoma (NHL): Initial Results from the PILOT Study
Sehgal, Alison R.
Godwin, John
Pribble, John
Wang, Lei
Thorpe, Jerill
Hildebrandt, Gerhard C.
BLOOD, 2019, 134
[44] Lisocabtagene Maraleucel (liso-cel) in R/R Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Primary Analysis of the Phase 1/2, Single-Arm, Multicenter TRANSCEND CLL 004 Study
Siddiqi, Tanya
Maloney, David G.
Kenderian, Saad S.
Brander, Danielle M.
Dorritie, Kathleen
Soumerai, Jacob
Riedell, Peter A.
Shah, Nirav N.
Nath, Rajneesh
Fakhri, Bita
Stephens, Deborah M.
Ma, Shuo
Feldman, Tatyana
Solomon, Scott R.
Schuster, Stephen J.
Perna, Serena K.
Tuazon, Sherilyn A.
Ou, San-San
Papp, Eniko
Chen, Yizhe
Wierda, William
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S320 - S321
[45] Lisocabtagene maraleucel (liso-cel) as second-line (2L) treatment (tx) for R/R large B-cell lymphoma (LBCL) in patients (pt) not intended for hematopoietic stem cell transplantation (HSCT): Patient-reported outcomes (PRO) from the phase 2 PILOT study.
Gordon, Leo I.
Hoda, Daanish
Shi, Ling
Guo, Shien
Liu, Fei Fei
Braverman, Julia
Dubowy, Ronald L.
Peng, Lily
Sehgal, Alison
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[46] Post-Infusion Monitoring Costs and Health Care Resource Utilization (HCRU) by Site of Care (SOC) in Patients With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) Receiving Lisocabtagene Maraleucel (liso-cel) Treatment in the TRANSCEND CLL 004 (TRANSCEND) Study
McGarvey, November
Lee, Abraham
Imanak, Ken
Tiwana, Simran K.
Garrison, Sean
Priyadarshini, Masoom
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S516 - S517
[47] Costs of Postinfusion Monitoring By Site of Care for Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL) Who Received Third-Line or Later Treatment with Lisocabtagene Maraleucel (liso-cel) in the Transcend NHL 001 and Outreach Trials
Palomba, M. Lia
Jun, Monika P.
Garcia, Jacob
Lymp, James
McGarvey, November
Gitlin, Matthew
Pelletier, Corey
Nguyen, Andy
BLOOD, 2020, 136
[48] Outpatient treatment with lisocabtagene maraleucel (liso-cel) across a variety of clinical sites from three ongoing clinical studies in relapsed/refractory (R/R) large B-cell lymphoma (LBCL).
Bachier, Carlos R.
Godwin, John E.
Andreadis, Charalambos
Palomba, Maria Lia
Abramson, Jeremy S.
Sehgal, Alison R.
Hildebrandt, Gerhard
Stevens, Don A.
Hoda, Daanish
Licitra, Edward J.
Siddiqi, Tanya
Farazi, Thalia Andrea
Kostic, Ana
Trede, Nikolaus S.
Wang, Lei
Lymp, James
Maloney, David G.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[49] Lisocabtagene Maraleucel (Liso-Cel) in R/R MCL: Primary Analysis Results From the MCL Cohort of the Single-Arm, Multicenter, Phase I Seamless Design TRANSCEND NHL 001 Study
Palomba, M. Lia
Siddiqi, Tanya
Gordon, Leo I.
Kamdar, Manali
Lunning, Matthew
Hirayama, Alexandre V.
Abramson, Jeremy S.
Arnason, Jon
Ghosh, Nilanjan
Mehta, Amitkumar
Andreadis, Charalambos
Solomon, Scott R.
Kostic, Ana
Dehner, Christine
Espinola, Ricardo
Peng, Lily
Ogasawara, Ken
Chattin, Amy
Wang, Michael
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S458 - S458
[50] A Retrospective Cohort Study of Treatment Outcomes of Adult Patients With Relapsed or Refractory Follicular Lymphoma (ReCORD-FL)
Salles, Gilles
Schuster, Stephen J.
Fischer, Luca
Kuruvilla, John
Patten, Piers Em
von Tresckow, Bastian
Smith, Sonali M.
Ubieto, Ana Isabel Jiminez
Davis, Keith L.
Nagar, Saurabh P.
Zhang, Jie
Bollu, Vamsi
Jousseaume, Etienne
Ramos, Roberto
Wang, Yucai
Link, Brian K.
HEMASPHERE, 2022, 6 (07):

← 1 2 3 4 5 →